September 19, 2023
Far Off Track: Funding for TB Research, 2018 – 2022
United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to 2 billion dollars […] in funding annually for tuberculosis research”…
August 16, 2023
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
July 20, 2023
2023 Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
July 12, 2023
Broadly Neutralizing Antibodies (bNAbs) and HIV Cure-Related Research
HIV has evolved multiple mechanisms to evade inhibition by antibodies, which are Y-shaped immune system proteins that normally play a key role in fending off or controlling infections.
July 11, 2023
An Activist’s Protocol Review Toolkit
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
June 20, 2023
2022 Annual Report
As we close another year of unprecedented challenges and achievements, I’m honored to share with you Treatment Action Group’s (TAG) 2022 Annual Report.
May 10, 2023
Why Hepatitis C Virus Care Remains Inaccessible
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
May 8, 2023
TAG Remarks Delivered at Multistakeholder Hearings, May, 2023
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
April 19, 2023
Nitrosamines and TB Medicines Information Note and Patient FAQs
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to help people affected by TB, advocates, policymakers, and implementers understand…